Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar
NCT04950764Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of seladelpar in primary biliary cholangitis (PBC) (6 cohorts), sponsored by Gilead Sciences. Primary endpoints: Maximum Observed Plasma Concentration at Day 28, Time to Maximum Plasma Concentration at Day 28 and 3 more. Started Nov 2021; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04950764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950764.